Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Vitreoretinal Degeneration Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Vitreoretinal Degeneration Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Vitreoretinal Degeneration in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Autosomal Dominant Lateral Temporal Lobe Epilepsy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Autosomal Dominant Lateral Temporal Lobe Epilepsy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Autosomal Dominant Lateral in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Fibrosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Fibrosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Fibrosis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Chagas Cardiomyopathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Chagas Cardiomyopathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Chagas Cardiomyopathy with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Read →
progressive familial intrahepatic cholestasis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
progressive familial intrahepatic cholestasis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate progressive familial in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Corneal Dystrophy, Congenital Stromal Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Corneal Dystrophy, Congenital Stromal Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Corneal Dystrophy, Congenital in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Autosomal Emery-Dreifuss Muscular Dystrophy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Autosomal Emery-Dreifuss Muscular Dystrophy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Autosomal Emery-Dreifuss in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Cerebellar Ataxia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Cerebellar Ataxia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Cerebellar Ataxia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Protein-Losing Enteropathies Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Protein-Losing Enteropathies Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Protein-Losing Enteropathies in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Hyperlipidemia, Familial Combined Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Hyperlipidemia, Familial Combined Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Hyperlipidemia, Familial in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Dystonia, Dopa-Responsive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Dystonia, Dopa-Responsive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Dystonia, Dopa-Responsive in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Mitochondrial Phosphate Carrier Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Mitochondrial Phosphate Carrier Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Mitochondrial Phosphate in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →